ADC/mAb
Recaticimab (PCSK9)
PCSK9
Recaticimab (PCSK9) is supplied by BOOKPHARM as an active ingredient in the adc/mab area. Antibody-drug conjugates and monoclonal antibodies available for out-licensing and business development. Business model: license-out. Listed status: NMPA approval.
Supply offerings
| Business line | Business model | Regulatory status |
|---|---|---|
| FDFADC/mAb | License-out | NMPA approval |
Supplied for pharmaceutical manufacturing and R&D by licensed and qualified entities. Not for human use as supplied. Availability is subject to regulatory approval in the buyer's jurisdiction.